Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

被引：0
|
作者：
Zhang, Xiaoying [1 ]
机构：
[1] Shandong Univ, Qilu Hosp, Dept Geriatr, Jinan 250012, Peoples R China
来源：
GLOBAL MEDICAL GENETICS | 2021年 / 08卷 / 04期
关键词：
D O I：
10.1055/s-0041-1731067
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [31] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer
    Liu, Sha
    Pan, Tao
    Wang, Ming-Kun
    Wang, Jie
    Zhang, Shuang
    Zhou, Ping
    CLINICAL DRUG INVESTIGATION, 2022, 42 (05) : 459 - 464
  • [32] Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
    Zhao, Jing
    Zou, Ming
    Lv, Jinyan
    Han, Yingmin
    Wang, Guangzhi
    Wang, Gang
    ONCOTARGETS AND THERAPY, 2018, 11 : 5545 - 5550
  • [33] Osimertinib shows promise in treating choroidal metastases and improving vision in EGFR T790M mutation-positive lung adenocarcinoma
    Keshwani, K.
    Roelofs, K.
    Hay, G.
    Lewis, R.
    Plowman, P.
    LUNG CANCER, 2020, 139 : S94 - S94
  • [34] Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review
    Hakozaki, Taiki
    Yomota, Makiko
    ONCOTARGETS AND THERAPY, 2019, 12 : 745 - 748
  • [35] Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
    Iams, W.
    Chae, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2249 - S2250
  • [36] Clinicopathologic features of lung cancer patients harboring de novo EGFR T790M mutation
    Lee, Young Joo
    Lee, Geon Kook
    Lee, Yeon-Su
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
    Pan, Guoqiang
    Chen, Kaiyan
    Yu, Xiaoqing
    Sheng, Jiamin
    Fan, Yun
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (06) : 2895 - 2905
  • [38] Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
    Peng, MuYun
    Wen, QiuYuan
    Wu, Xia
    Yu, FengLei
    Liu, WenLiang
    THORACIC CANCER, 2020, 11 (09) : 2704 - 2708
  • [39] Mechanisms of acquired resistance to osimertinib in advanced NSCLC with EGFR T790M mutation (LOGIK1607)
    Yamaguchi, Masafumi
    Osoegawa, Atsushi
    Nakamura, Tomomi
    Morinaga, Ryotaro
    Tanaka, Kentaro
    Kashiwabara, Kosuke
    Miura, Takashi
    Suetsugu, Takayuki
    Taguchi, Kenichi
    Nabeshima, Kazuki
    Kishimoto, Junji
    Sakai, Kazuko
    Nishio, Kazuto
    Sugio, Kenji
    CANCER SCIENCE, 2021, 112 : 567 - 567
  • [40] Association between BIM Deletion Polymorphism and Efficacy of Osimertinib in Advanced EGFR T790M NSCLC Patients
    Li, X.
    Zhang, D.
    Wang, R. Z.
    Li, B.
    Guo, M.
    Zou, B.
    Yu, J.
    Wang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E87 - E87
12345